Ohio University and its inventors have sold partial royalty...

Ohio University and its inventors have sold partial royalty income rights to its license for the growth hormone antagonist drug SOMAVERT® (pegvisomant for injection)for $52m

If the combined therapy with ATL1103 is being adopted at this stage, the value of ATL1103 would increase further from its stand alone application.

Pfizer should be in the forefront to be interested in ATL1103, not only because ATL1103 could be a more advanced theraphy for Acromegaly compare to SOMAVERT®, now it also has a combined threpeutic possibility.

It make perfect sense that by acquiring the license to ATL1103 for Acromegaly, Pfizer would strategically ensure that its acromegaly market can be protected for the future.


JIMO